The authors comment on the need and urgency of the need for an effective dengue vaccine. Topics covered include the complexity of developing a vaccine against all four dengue virus (DENV) serotypes, questions on the efficacy of the Sanofi dengue vaccine and the potential efficacy of a tetravalent live attenuated vaccine formulation referred to as TV003.